Dyslipidemia

How technology, innovation, and preventive care drove the last 10 years of improved public heart health.

Earlier this year, the American College of Cardiology and the American Heart Association updated treatment guidelines for the primary prevention of cardiovascular disease. They discourage the use of aspirin for this purpose, but in high-risk patients who are not at risk of bleeding, aspirin continues to be part of combination treatment regimens. In this slideshow, we highlight recent findings on aspirin use.

How findings from AHA show early ANGPTL3 and APOC3 benefits in cardiometabolic health, via liver protein targeting.

Discussing how new information released in 2019 has impacted the way cardiologists view aspirin use for primary and secondary prevention of cardiovascular events.

Novartis AG is set to acquire The Medicines Company in a $9.7 billion deal that is set to be completed in the first quarter of 2020.

Results of the CITU study are revealing more about the different impacts e-cigarette and tobacco use has on a patient's lipid profile.

A new analysis from the University of Minnesota has found many patients with and without an indication for regular low dose aspirin use are under or overusing the medication.

A new analysis from Johns Hopkins School of Medicine has found patients in the South, Midwest, and West were all more likely to report poorer healthcare-related quality of life when compared to patients in the Northeast.

A conversation with Deepak Bhatt, MD, MPH, discussing the most impactful advances in cardiology in 2019 and what he sees as the most important advances in the past decade as 2019 comes to a close.

The study author provides insight into the benefit of inclisiran in at-risk patients with ASCVD.

An analysis of 4 phase 3 clinical trials examining the use of bempedoic acid for lowering LDL cholesterol was presented at AHA 2019.

How preventive care strategy adherence could bolster heart disease risk reduction in entire families.

Promising drug inclisiran shows significant LDL cholesterol reduction in patients with familial hypercholesterolemia.

Results of ORION-9 reveal inclisiran has the potential to treat familial hypercholesterolemia with twice-a-year injections.

The addition of IPE significantly slowed coronary plaque progression as compared to placebo over 9 months for 4 of the 5 secondary end points.

A recent analysis of the FRANCE-TAVI registry presented at AHA 2019 has found self-expanding transcatheter heart valves were associated with an increased risk of all-cause mortality following TAVR.

A new study from AHA 2019 has found that use of rivaroxaban rather than antiplatelet therapy after TAVR increased a patient's risk of death and bleeding events.

Results of the ISCHEMIA trial were revealed at AHA 2019 and revealed little overall benefit of an invasive approach but saw improved angina control in patients with previous angina.

The ORION-10 trial revealed 300 mg inclisiran twice-yearly reduced LDL-C levels by 58% in patients with atherosclerotic cardiovascular disease.

A new study from investigators in Australia has found nearly 1 in 5 patients in a cardiac rehabilitation program suffer from at least moderate depression, anxiety, or stress.

A new study from the European Heart Journal is contradicting a January 2019 FDA warning that paclitaxel-coated devices were linked to an increased risk of death.

A study from investigators in Europe found the CCS, ACC/AHA, and NICE guidelines for statin use may be more effective at preventing ASCVD events than ESC/EAS or USPSTF guidelines.

A recent study found the lifetime risk of peripheral artery disease in black patients was around 30% while Hispanic and white patients had prevalence rates around 20%.

Initial PCSK9 inhibitor plus statin therapy helped hospitalized patients achieve LDL-C

A recent study found that county-level poverty prevalence correlated with both heart failure and coronary heart disease mortality rates.